Cardiotoxic drugs: clinical monitoring and decision making.
Wu
Audrey H
AH
University of Michigan Health Systems, Cardiovascular Center, Ann Arbor, MI 48109-5853, USA. ahwu@med.umich.edu
D018943:Anthracyclines / Q000009:adverse effects; D044966:Anti-Retroviral Agents / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D009202:Cardiomyopathies / Q000139:chemically induced*; D054715:Cardiotoxins / Q000009:adverse effects*; D003657:Decision Making; D006801:Humans; D015182:Lymphatic Irradiation / Q000009:adverse effects; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D011720:Pyrazoles / Q000009:adverse effects; D011743:Pyrimidines / Q000009:adverse effects; D019966:Substance-Related Disorders / Q000150:complications; D045162:Thiazolidinediones / Q000009:adverse effects
C108123:4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine; D018943:Anthracyclines; D044966:Anti-Retroviral Agents; D000911:Antibodies, Monoclonal; D054715:Cardiotoxins; D011720:Pyrazoles; D011743:Pyrimidines; D045162:Thiazolidinediones